Observation unit treatment of heart failure with nesiritide: Results from the proaction trial

W. F. Peacock IV, R. Holland, R. Gyarmathy, L. Dunbar, M. Klapholz, D. P. Horton, G. De Lissovoy, C. L. Emerman

Research output: Contribution to journalArticlepeer-review

Abstract

This was a multicenter, randomized, double-blind, placebo-controlled pilot study, evaluating the safety and efficacy of a standard care treatment regimen with the addition of either nesiritide or placebo (SCP) in 237 Emergency Department (ED)/Observation Unit (OU) patients with decompensated heart failure (HF). Efficacy measures included initial admission, length of hospital stay (LOS), and inpatient rehospitalization through 30 days. Compared to the standard care group, patients who also received nesiritide had 11% fewer inpatient hospital admissions at the index ED visit (55% SCP, 49% nesiritide, p = 0.436), and 57% fewer inpatient hospitalizations within 30 days after discharge from the index hospitalization (23% SCP, 10% nesiritide, p = 0.058). The duration of rehospitalization was shorter for nesiritide patients (median LOS 2.5 vs. 6.5 days, p = 0.032). The incidence of symptomatic hypotension was low and did not differ between the groups. This study showed that nesiritide is safe when used in the emergency department, observation units, or similar settings.

Original languageEnglish (US)
Pages (from-to)243-252
Number of pages10
JournalJournal of Emergency Medicine
Volume29
Issue number3
DOIs
StatePublished - Oct 2005
Externally publishedYes

Keywords

  • Decompensated heart failure
  • Emergency Department
  • Hospitalization
  • Length of stay
  • Nesiritide

ASJC Scopus subject areas

  • Emergency Medicine

Fingerprint Dive into the research topics of 'Observation unit treatment of heart failure with nesiritide: Results from the proaction trial'. Together they form a unique fingerprint.

Cite this